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Abstract
Objective: To compare the efficacy, safety, and tolerability of azithromycin and amoxicillin in the treatment of patients with infectious 
exacerbation of chronic obstructive pulmonary disease. Methods: This study was conducted at six medical centers across Brazil and included 
109 patients from 33 to 82 years of age. Of those, 102 were randomized to receive either azithromycin (500 mg/day for three days, n = 49) 
or amoxicillin (500 mg every eight hours for ten days, n = 53). The patients were evaluated at the study outset, on day ten, and at one 
month. Based on the clinical evaluation of the signs and symptoms present on day ten and at one month, the outcomes were classified 
as cure, improvement, or treatment failure. The microbiological evaluation was made through the culture of sputum samples that were 
considered appropriate samples only after leukocyte counts and Gram staining. Secondary efficacy evaluations were made in order to analyze 
symptoms (cough, dyspnea, and expectoration) and pulmonary function. Results: There were no differences between the groups treated with 
azithromycin or amoxicillin in terms of the percentages of cases in which the outcomes were classified as cure or improvement: 85% vs. 78% 
(p = 0.368) on day ten; and 83% vs. 78% (p = 0.571) at one month. Similarly, there were no significant differences between the two groups 
in the secondary efficacy variables or the incidence of adverse effects. Conclusion: Azithromycin and amoxicillin present similar efficacy and 
tolerability in the treatment of acute exacerbation of chronic obstructive pulmonary disease.
Keywords: Amoxicillin/therapeutic use; Azithromycin/therapeutic use; Bronchitis, chronic/drug therapy;Pulmonary disease, chronic 
obstructive/drug therapy; Comparative study.
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Introduction
Chronic obstructive pulmonary disease (COPD) 
is a condition characterized by progressive airflow 
limitation that is not fully reversible.(1) Most of the 
cases occur in patients who are smokers or former 
smokers, and COPD is characterized by an accel-
erated decrease in the forced expiratory volume 
in one second.(2) In addition, COPD presents a 
spectrum of pathological alterations and clinical 
manifestations.(3) Within this spectrum, chronic 
bronchitis is defined as chronic productive cough 
for at least three months during two consecutive 
years.(4) Chronic bronchitis is characterized by the 
obstruction of small-diameter airways and increased 
mucous production. In addition, many patients 
with chronic bronchitis present varying degrees of 
emphysema, characterized by the destruction of air 
spaces and loss of lung elasticity.(3) Therefore, it is 
sometimes difficult to discern the individual contri-
bution of these two pathological processes, chronic 
bronchitis and emphysema, to the clinical manifes-
tations in a patient. Although the epidemiology of 
COPD is not well known in Brazil yet, an epidemio-
logical population-based study, conducted in the 
metropolitan area of the city of São Paulo, demon-
strated that 15.8% of individuals above 40 years of 
age meet the criteria for COPD.(5) In addition, COPD 
was the fourth leading cause of hospitalizations in 
Brazil in adults in 2002.(6)
Patients with COPD present frequent episodes of 
infectious exacerbation. These episodes are charac-
terized by rapid worsening of pulmonary function, 
worsening of airway obstruction, and increased 
mucus production. It is estimated that patients with 
COPD have, on average, up to three annual episodes 
of infectious exacerbation.(4) Despite the multifac-
torial origin of the exacerbation, infection is its 
principal cause, being responsible for 50 to 80% of 
the cases.(4,6,7) Among these, the most frequent are 
the bacterial infections, and the most commonly 
found pathogens are Haemophilus influenzae, 
Moraxella catarrhalis and Streptococcus pneu-
moniae.(6) Compared to a placebo, antibiotics are 
considered efficacious, shortening the duration of 
the infectious exacerbation.(8,9) Therefore, patients 
with infectious exacerbation of COPD frequently 
require treatment with oral broad-spectrum antibi-
otics, which can be administered in a reasonable 
manner, with safety and expected efficacy in most 
cases. Various classes of antibiotics are currently 
available for this purpose. The objective of the 
present study was to compare the efficacy, safety 
and tolerability of two oral antibiotics, azithromycin 
and amoxicillin, in the outpatient treatment of indi-
viduals with infectious exacerbation of COPD.
Methods
The patients who were considered for inclusion 
in the study were between 30 and 70 years of age 
and had been diagnosed with infectious exacerba-
tion of COPD. The diagnosis was confirmed based 
on the presence of at least two of the following 
criteria: increased cough, increased expectoration 
or worsening of dyspnea. Subjects were required 
to have been under outpatient treatment and to 
have had a simple chest X-ray that showed no 
evidence of pneumonia performed within the 
48 hours preceding their inclusion in the study. 
Female patients who were breastfeeding, pregnant 
or planning to become pregnant (during the study 
or up to one month after the end of the study) 
were excluded, as were women of childbearing age 
who were not using some efficacious method of 
contraception. Additional exclusion criteria were 
as follows: having a history of hypersensitivity to 
azithromycin or amoxicillin; undergoing treatment 
with systemic antibiotics within the two weeks 
preceding the study outset; use of antibiotics fore-
seen for other clinical condition, as well as the use 
of allopurinol, probenecid, digoxin, warfarin or 
ergotamine during the study; having a history of 
human immunodeficiency virus infection, acute 
bronchitis or bronchiectasis; having been suspected 
of having lung abscess or empyema; having a 
history of or having been suspected of having active 
tuberculosis, cystic fibrosis or lung cancer (primary 
or metastatic); having any clinical or psychological 
condition deemed by the examiner to potentially 
impair participation in the study; having a history of 
alcohol or substance abuse; undergoing treatment 
with immunosuppressive drugs, including doses of 
corticosteroids higher than the equivalent to 10 mg/
day of prednisone; presenting any of the following 
laboratory test results: leukocyte count lower than 
2500/mm3 – neutrophil count lower than 1000/
mm3 – elevated transaminase levels of over twice 
the upper limit of normality – alkaline phosphatase 
or bilirubin levels greater than 1.5 times the upper 
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limit of normality; donating blood during the study 
or within one month after the conclusion of the 
study; participating in clinical studies, including this 
one, within one month prior to the inclusion in the 
present study.
All of the patients included in the study gave 
written informed consent. The protocol was 
approved by the ethics in research committee of each 
of the six centers participating in the study, which 
was conducted in accordance with the ethical prin-
ciples of the Declaration of Helsinki, the Guidelines 
for Good Clinical Practice in Clinical Trials and the 
federal resolutions that regulate clinical research in 
Brazil. 
The patients considered for inclusion in the study 
were evaluated in the initial medical visit, during 
which clinical histories were taken, complete physical 
examinations were performed, laboratory tests were 
conducted, simple chest X rays were taken, spirom-
etry was performed, and purulent sputum (recently 
expectorated) was submitted to microbiological 
analysis. Evaluation of sputum was performed after 
Gram staining and culture of samples considered 
appropriate, defined as those containing more than 
25 leukocytes and less than 10 squamous epithelial 
cells per low-power microscopic field (×100).(10) The 
patients were then randomly allocated to receive 
azithromycin (500 mg/day, p.o., for three consec-
utive days) or amoxicillin (500 mg/8 h, p.o., for 
ten consecutive days). After ten days, the patients 
were again examined: histories were re-taken; vital 
signs were checked; spirometry was performed; and 
another sputum sample was submitted to microbio-
logical evaluation. The third and final examination 
was performed at approximately one month after 
the initiation of treatment and included the same 
procedures conducted in the second examination. 
Patients were required to report all medications taken 
during the study. The quantities of azithromycin and 
amoxicillin used by the patients were calculated in 
order to evaluate adherence to the treatment.
In order to evaluate efficacy and safety, two 
patient samples were analyzed. The evaluation of 
safety was performed with an intention-to-treat 
patient sample, comprising all of the patients who 
took at least one dose of one of the drugs used 
in the study. Another patient sample was evalu-
ated per protocol (PP sample) and was composed 
of the patients who took the appropriate drug 
dosage (defined as between 80 and 100% of the 
pills prescribed) and had not violated the protocol 
in any way. 
In the second and third examinations, the clin-
ical response of the patients was classified as cure, 
improvement or treatment failure. Cure was defined 
as the resolution of the signs and symptoms of acute 
exacerbation, which reverted to the usual pattern 
for each patient. Improvement was defined as the 
disappearance of fever, with incomplete resolution 
of the other signs and symptoms, without the need 
for additional antibiotics. Treatment failure was 
defined as the lack of resolution of signs and symp-
toms or the need for further use of antibiotics. The 
primary evaluation of treatment efficacy was based 
on the percentage of patients who presented cure 
or improvement. The secondary parameters of effi-
cacy were the evaluations of signs and symptoms 
and the results of microbiological evaluations.
All adverse events reported by the patients, 
or observed by the examiners, over the course of 
the study, were recorded. The incidence of serious 
adverse events, defined as any events that resulted 
in death, hospitalization, prolongation of hospitali-
zation, persistent/significant incapacitation, or risk 
to the life of the patient, was also analyzed. Cases 
in which the treatment was discontinued, whether 
due to its inefficacy or to related adverse events, 
were evaluated.
The demographic variables and baseline patient 
characteristics were compared through the calcula-
tion of descriptive measurements and analysis of 
variance (ANOVA) for quantitative variables, and 
using the chi-square test or Fisher’s exact test, as 
needed, for qualitative variables. The differences 
between the percentages of patients presenting 
cure or improvement in each group were compared 
using tests of proportions and their respective 95% 
confidence intervals. The same statistical technique 
was applied in the microbiological evaluation. 
The results of the pulmonary function tests were 
analyzed using ANOVA for repeated measurements. 
The statistical analyses were performed using the 
SAS program (Statistical Analysis System, Cary, NC, 
USA). All of the hypothesis tests were two-tailed, 
and the level of significance was set at 5%.
Results
Of the 109 patients included in the study, 102 
took at least one dose of the prescribed antibiotic 
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and constituted the intention-to-treat sample. Of 
those 102 patients, 19 discontinued the treatment 
for one of the following reasons: adverse events 
(n = 11); lack of treatment efficacy (n = 4); with-
drawal of informed consent (n = 2); and protocol 
violation (n = 2). Therefore, 83 intention-to-treat 
sample patients completed the study: 41 treated 
with azithromycin; and 42 treated with amoxicillin. 
The mean age of the 102 participants in the study 
was 60 years (range, 33-82 years), and 59 patients 
were male (58%). These and other demographic and 
clinical characteristics are shown in Table 1. There 
were no significant differences between the two 
groups in terms of any of these characteristics.
On day ten of the treatment, 97 patients were 
appraisable for clinical response. Of the 5 patients 
in the intention-to-treat sample who were not 
appraisable, 2 had been treated with azithromycin 
and 3 with amoxicillin. There were no statistically 
significant differences between the two groups 
when we compared the percentages of patients 
presenting cure or improvement. Table 2 shows that 
these percentages were as follows: 85% in the group 
treated com azithromycin, and 78% in the group 
treated with amoxicillin (p = 0.368). One month 
after the end of the treatment, it was possible to 
evaluate the clinical response in 96 cases. Of the 6 
patients who were not appraisable, 3 had received 
azithromycin, and 3 had received amoxicillin. Once 
again, there were no statistically significant differ-
ences between the two groups when we compared 
the percentages of patients presenting cure or 
improvement: 83% and 78% in the groups treated 
with azithromycin and amoxicillin, respectively (p = 
0.571). Similar results were found when the analysis 
of efficacy was performed in the PP sample (data 
not shown).
The microbiological response was evaluated on 
day ten in 97 patients and after one month in 86 
patients. The pathogens most frequently isolated in 
culture, regardless of the phase of the treatment, 
were the bacteria of the following types: Moraxella 
catarrhalis, Streptococcus alpha hemolyticus, 
Haemophilus influenzae, Pseudomonas aeruginosa 
and Klebsiella pneumoniae (Table 3). There were 
no differences between the two groups when we 
Table 1 – Demographic characteristics of the patients studied.
Variable Azithromycin (n = 49) Amoxicillin (n = 53) p
Age, years
Range 41 to 77 33 to 82
Mean 60.4 59.8 0.740
Gender
Males 32 27 0.142
Females 17 26 0.142
Current or former smoking 47 51 0.927
Symptom intensity at the study outset
Cough
Absent 0 0 0.414
Mild 2 5 0.414
Moderate 33 37 0.414
Severe 14 11 0.414
Expectoration
Absent 0 0 0.326
Mild 4 9 0.326
Moderate 31 33 0.326
Severe 14 11 0.326
Dyspnea
Absent 10 7 0.810
Mild 7 8 0.810
Moderate 28 33 0.810
Severe 4 5 0.810
Intention-to-treat sample, n = 102.
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compared the various categories of microbiological 
responses (data not shown). Similarly, there were 
no differences when we evaluated cough, expecto-
ration and dyspnea (Table 4). Nor were there any 
differences in pulmonary function on day 10 or at 
one month after treatment outset (Table 5).
In the group treated with azithromycin, 96% of 
the patients took all three doses prescribed. In the 
group treated with amoxicillin, 92% of the patients 
took at least 90% of the pills prescribed. A total of 
33 patients treated with azithromycin had at least 
one adverse event, compared with 27 of the patients 
treated with amoxicillin. The principal adverse events 
attributed to the treatment were of a gastrointes-
tinal nature (nausea, epigastric pain and diarrhea). 
Such events occurred in 5 patients treated with 
azithromycin and in 9 patients treated with amoxi-
cillin. A total of 5 patients treated with azithromycin 
and 2 treated with amoxicillin presented adverse 
events considered serious according to the protocol. 
Such events included worsening of the respiratory 
condition with bronchoconstriction (in 4 patients), 
convulsive seizures (in 1) and rib fracture (in 1). None 
of these events were considered to be secondary to 
the use of the antibiotics in the study.
Discussion
The present study demonstrated that azithro-
mycin and amoxicillin present similar efficacy and 
tolerability in patients with infectious exacerba-
tion of COPD. Clinical response rate, defined as 
the percentage of patients who achieved cure or 
improvement of the signs and symptoms of the 
infectious exacerbation condition, was similar in the 
two groups and comparable to the results obtained 
Table 2 - Comparative efficacy between azithromycin and amoxicillin, on day 10 and on day 30 after the initiation 
of treatment.
On day 10 p
Clinical response Azithromycin (n = 47) Amoxicillin (n = 50)
Cure or improvement 85% 78% 0.368
Treatment failure 15% 22%
On day 30
Clinical response Azithromycin (n = 46) Amoxicillin (n = 50)
Cure or improvement 83% 78% 0.571
Treatment failure 17% 22%
Table 3 - Clinical evolution of patients and bacteria isolated per examination.
Pathogen Nº of patients with isolated bacteria (clinical classification of the evolution)
1 2 3
Inclusion Day10 Day 30
Haemophilus influenzae 3 1 
(treatment failure)
1 
(treatment failure)
Haemophilus parainfluenzae 1
(cured)
Klebsiella pneumoniae 1 7
(2 cured)
7
Moraxella catarrhalis 10  (1 cured)
(4 improvements)
(2 treatment failures)
3
(all cured)
Pseudomonas aeruginosa 2 3 
(2 cured)
(1 improvement)
1
(cured)
Streptococcus pneumoniae 5 2 
(1 improvement) 
(1 treatment failure)
3
(2 cured)
(1 treatment failure)
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in other studies with a similar design. Similarly, there 
were no significant differences in other param-
eters of efficacy or in the toxicity attributed to the 
treatment.
Various factors must be considered when 
choosing antibiotics for the treatment of patients 
with infectious exacerbation of COPD.(11) Noteworthy 
among these factors are the spectrum of action, 
the expected rate of bacterial resistance, conven-
ient dosage schedule and adequate penetration into 
respiratory secretions. Various antibiotics used in 
the treatment of infectious exacerbation of COPD 
have many of these characteristics. Azithromycin is 
a broad-spectrum macrolide antibiotic, indicated 
for the pathogens most commonly implicated in 
community-acquired respiratory infections.(12) In an 
international study, in which the rates of in vitro 
resistance to various antibiotics were compared 
among respiratory pathogens, the results of the 
samples from Brazil revealed that S. pneumoniae 
and H. influenzae presented, respectively, 95% and 
100% sensitivity to azithromycin.(13) The adminis-
tration of azithromycin for three days guarantees 
adequate antibiotic levels for up to ten days. This 
pharmacokinetic property makes azithromycin an 
antibiotic with a quite satisfactory dose schedule. In 
addition, azithromycin presents excellent penetra-
tion into respiratory secretions.(14)
Table 4 - Comparison of symptoms between the two groups, on day 10 and on day 30 after the initiation of 
treatment.
Day 10 Day 30
Azithromycin Amoxicillin Azithromycin Amoxicillin
n % n % n % n %
Cough Severe 3 6.4 2 4 0 0.0 2 4.4
Moderate 14 29.8 14 28 10 24.4 8 17.8
Mild 25 53.2 32 64 25 61.0 27 60.0
Absent 5 10.6 2 4 6 14.6 8 17.8
Total 47 100.0 50 100 41 100.0 45 100.0
Expectoration Severe 1 2.1 1 2 1 2.4 0 0.0
Moderate 13 27.7 20 40 5 12.2 4 8.9
Mild 27 57.5 22 44 24 58.5 30 66.7
Absent 6 12.8 7 14 11 26.8 11 24.4
Total 47 100.0 50 100 41 100.0 45 100.0
Dyspnea Severe 4 8.5 2 4 0 0.0 2 4.4
Moderate 14 29.8 15 30 6 14.6 5 11.1
Mild 15 31.9 19 38 20 48.8 23 51.1
Absent 14 29.8 14 28 15 36.6 15 33.3
Total 47 100.0 50 100 41 100.0 45 100.0
p > 0.05 for the comparisons between the groups.
Table 5 - Comparison of pulmonary function between the two groups on day 10 and on day 30 after the initiation 
of treatment.
Azithromycin Amoxicillin
Study outset 
 (n = 49)
On day 10
(n = 44)
On day 30
(n = 40)
Study outset 
(n = 53)
On day 10 
(n = 49)
On day 30 
(n = 41)
FEV1 (L) 1.6 ± 0.8 1.7 ± 0.8 1.8 ± 0.8 1.6 ± 0.9 1.6 ± 0.8 1.9 ± 0.9
[% predicted] 66.1 ± 0.3 70.25 ± 0.3 74.4 ± 0.3 66.9 ± 0.4 66.9 ± 0.3 79.5 ± 0.4
VC (L) 2.6 ± 0.9 2.7 ± 1.0 2.9 ± 0.9 2.7 ± 1.1 2.7 ± 1.0 2.9 ± 1.1
[% predicted] 84.7 ± 0.3 87.9 ± 0.33 94.4 ± 0.3 89.4 ± 0.36 89.4 ± 0.33 96.0 ± 0.36
Values are shown as mean ± standard deviation. FEV1: forced expiratory volume in the first second; VC: vital capacity. p > 0.05 for 
the comparisons between the groups.
Comparison between azithromycin and amoxicillin in the treatment of infectious exacerbation of 
chronic obstructive pulmonary disease
J Bras Pneumol. 2007;33(1):43-50
49
Other randomized studies have compared 
azithromycin and amoxicillin in the treatment of 
patients with acute exacerbation of chronic bron-
chitis. In some studies, amoxicillin was administered 
in combination with clavulanic acid, an inhib-
itor of some of the beta-lactamases produced by 
respiratory pathogens. A meta-analysis comprising 
fourteen randomized studies in which azithromycin 
and amoxicillin were compared showed that the 
two present similar efficacy, and that the incidence 
of adverse events was lower among individuals 
receiving amoxicillin, with or without clavulanic 
acid.(15) The efficacy of azithromycin has been 
shown to be equivalent to that of other classes 
of antibiotics, including moxifloxacin,(16) levo-
floxacin(17) and pivampicillin,(18) as well as to that of 
other macrolides, including roxithromycin,(19) clari-
thromycin(20) and dirithromycin.(21, 22)
Due to the similar efficacy of the various anti-
biotics used in the treatment of acute exacerbation 
of chronic bronchitis, it is of interest to evaluate 
which of the drugs employed are associated with a 
more satisfactory pharmacoeconomic profile. In a 
Latin-American study, it was estimated that anti-
biotics account for only 19.7% of the direct cost 
of treating infectious exacerbations.(23) Although 
this is a relatively low proportion of the total cost 
of the treatment, there might be antibiotics with 
more favorable cost-effectiveness ratios. In other 
words, it is possible to minimize or even invert the 
cost difference among different antibiotics when 
other aspects of the treatment, such as efficacy and 
toxicity, are taken into account. There have been few 
studies addressing this issue, the results of which 
are applicable on a large-scale.(24) In a retrospec-
tive study, the use of third-generation antibiotics 
(azithromycin, ciprofloxacin and amoxicillin/clavu-
lanic acid) in comparison to that of first-generation 
antibiotics (amoxicillin, sulfamethoxazole/trimetho-
prim, erythromycin and tetracycline) was found to 
be associated with lower rates of treatment failure/
hospitalization, longer intervals between exacerba-
tion episodes and (a tendency toward) lower overall 
treatment costs.(25)
The results of the present study confirm the 
efficacy and tolerability of azithromycin for the 
outpatient treatment of episodes of infectious 
exacerbation of COPD. In this context, it can be 
expected that the treatment with azithromycin 
will promote cure or clinical improvement in most 
patients, with acceptable toxicity and costs. Taking 
these characteristics into consideration, in addi-
tion to the convenient dosage schedule offered by 
azithromycin, the use of this drug can be considered 
one of the treatments of choice for patients with 
infectious exacerbation of COPD.
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